Dr. Jonas Zeller joined InnoMedica Holding AG in 2013 as Head of Finance and Administration. He brings experience in Financial Management, and was a lecturer of Business Valuation at the University of Bern and the Bern-Rochester Executive MBA program. He obtained a doctorate from the Institute of Financial Management at the University of Bern, where his research examined the interaction between age and economic efficiency of enterprises. Prior to his doctoral thesis, he had a role as an analyst in the Economic Research Department at Credit Suisse in Zürich. His graduate studies were at the University of Bern and the Simon Graduate School of Business at the University of Rochester in New York.

Stefanie Dobitz is Innovation & Startup Advisor for Health, Medicine, and Life Sciences at the University of Bern and Inselspital, Bern University Hospital. Her focus is on supporting and connecting people for their innovative and successful entrepreneurial journey. Stefanie earned her doctoral thesis from ETH Zurich studying the synthesis and biological evaluation of oligoproline-based peptide ligands for tumor targeting, and holds a CAS in innovation management. Prior joining the University of Bern, Stefanie worked as sales manager for a Swiss CDMO, wherein she supported the pharma and biotech industry in the lead finding of future drug candidates, medical devices, as well as cosmetics.

I am a senior scientist within the Translational Epidemiology team at Bristol Myers Squibb in Switzerland. My work focusses on enhancing and transforming real world and omics data and running statistical analyses utilizing real world evidence combined with genomic features to support research questions in the preclinical space..

Nadine C. Martin is Head of Innovation Management at sitem-insel AG since 2015. Her particular interest goes to Open Innovation in the Life Science sector and she focusses on activities that inspire an innovation culture for all stakeholders to think and act out of the box in order to translate better and faster. She holds an MD and a specialist degrees in Anaesthesiology and in pharmaceutical medicine and a certificate in Innovation Management. She has a long standing experience in pharmaceutical industry and served on boards of professional associations, and as VP on the Board of LIH and now heads the Scientific Council of the FNR, besides being an expert judge and mentor at MassChallenge Switzerland”.

David Roura Padrosa is the co-founder and CEO of inSEIT AG, a startup affiliated with the University of Bern, specializing in rational biocatalyst immobilization. He completed his PhD in chemical biology at the University of Nottingham in 2019 and continued his research in applied biocatalysis at the University of Bern under the supervision of Prof. Paradisi. David's research focused on discovering new biocatalysts and their application in synthesizing valuable chemicals, with an emphasis on biocatalysis and flow chemistry. More recently, he also developed novel bioinformatic tools and workflows to optimize enzyme immobilization protocols. He received the BRIDGE Proof of Concept fellowship from the Swiss National Foundation, an individual scholarship that supports early career scientists in bridging the gap towards the creation of Swiss-based startups. This recognition underscores the potential of inSEIT to drive innovation and contribute to the growth of the biotech industry. Founded in 2022, inSEIT AG builds upon cutting-edge bioinformatic workflows to unlock the full potential of immobilized enzymes, thereby enhancing the repertoire of available enzymes for the chemical industry. The company's vision is to provide advanced biocatalytic tools, particularly in the areas of chiral molecule synthesis and late-stage functionalization. With a clear commitment to advancing sustainable chemistry and delivering impactful innovations, inSEIT has already created a toolbox of immobilized enzymes and advanced in the validation of its bioinformatic tools.

I am a senior scientist at Bristol Myers Squibb with a strong background in immunology and extensive hands-on experience in data science. I began my career in the telecommunications industry, where I worked in several projects as a data analyst. Driven by a passion for healthcare, I transitioned to the pharmaceutical sector, leveraging my expertise in data analysis to advance research and development programs. My unique blend of molecular life sciences knowledge and data analytics skills enables me to address scientific questions in a targeted manner while keeping the research question at the forefront. In the current role, I’m contributing to the integration of multi-modal real-world data in research programs, supporting evidence-based decision-making.

In 2020 Daniel received his Ph.D. in Chemistry and Molecular Sciences from the University of Bern under the supervision of Prof. Jean-Louis Reymond. His main research interest is efficient machine learning and data visualization applied to natural sciences, focusing on the intersection of chemistry and biology. After a two-year stay as a permanent research staff member at IBM Research in the Team of Teodoro Laino working on machine learning for biocatalysis, he started as a postdoctoral researcher in the group of Prof. Pierre Vandergheynst at EPFL. Over the last 5 years, Daniel has authored and co-authored more than 20 papers on the application of AI to chemistry, ranging from chemical synthesis prediction to exploration of chemical synthesis space and development of novel methods for computational analysis of drugs, biomolecules and metabolites.